Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Non-Current Deffered Revenue (2020 - 2025)

Cytek Biosciences (CTKB) has disclosed Non-Current Deffered Revenue for 6 consecutive years, with $18.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non-Current Deffered Revenue rose 13.92% year-over-year to $18.3 million, compared with a TTM value of $18.3 million through Dec 2025, up 13.92%, and an annual FY2025 reading of $18.3 million, up 13.92% over the prior year.
  • Non-Current Deffered Revenue was $18.3 million for Q4 2025 at Cytek Biosciences, up from $16.3 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $18.3 million in Q4 2025 and bottomed at $6.3 million in Q2 2021.
  • Average Non-Current Deffered Revenue over 5 years is $13.3 million, with a median of $14.8 million recorded in 2024.
  • The sharpest move saw Non-Current Deffered Revenue skyrocketed 183.28% in 2021, then dropped 12.4% in 2024.
  • Year by year, Non-Current Deffered Revenue stood at $9.8 million in 2021, then soared by 34.06% to $13.1 million in 2022, then grew by 15.3% to $15.1 million in 2023, then grew by 6.38% to $16.1 million in 2024, then rose by 13.92% to $18.3 million in 2025.
  • Business Quant data shows Non-Current Deffered Revenue for CTKB at $18.3 million in Q4 2025, $16.3 million in Q3 2025, and $16.6 million in Q2 2025.